Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00167999

Enrollment

200

Registered

2005-09-14

Start date

2005-02-28

Completion date

Unknown

Last updated

2007-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections

Keywords

Bacterial Infections

Brief summary

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Interventions

DRUGpiperacillin-tazobactam

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to No maximum

Healthy volunteers

Inclusion criteria

* Eligible patients of either sex, 15 years of age or older * Patients who are admitted to the department of hematology and oncology * Provide written informed consent

Exclusion criteria

* Patients who have hypersensitivity to β-lactam antibiotics * Female who are pregnant or breast-feeding * Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026